Ben Holmes, DVM

Approximately how many adult patients with spinal muscular atrophy (SMA) have you encountered in your clinical practice? Approximately how many adult patients with spinal muscular atrophy (SMA) have you encountered in your clinical practice?

What is the greatest challenge facing your clinical team in the treatment and management of adult patients with SMA? What is the greatest challenge facing your clinical team in the treatment and management of adult patients with SMA?

Please rate your level

Immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis (RA) and spondyloarthritides, are common, clinically diverse and chronic. While significant variations in population distribution, tissue localisation, clinical phenotypes and therapeutic responses are apparent between different IMIDs, they share many similar pathophysiological mechanisms.1–3 Small-molecule Janus kinase (JAK) inhibitors are a therapeutic class for the management of IMIDs.4 5 Although certain adverse ev

Associate Professor, Department of Neurology at NYU Grossman School of Medicine Director, Division of Child Neurology Director, Neurofibromatosis Program

Neurofibromatosis type 1 (NF1) is a debilitating and disfiguring condition characterized by benign plexiform neurofibromas (PN) that develop along nerve sheaths throughout the body. In this 1-hour video activity, two renowned NF1 PN experts discuss strategies to improve early identification of NF1 PN, best screening and diagnostic practices, t

Chemotherapy patients often experience nausea and vomiting that not only has a negative impact on the patient’s quality of life but can also result in unplanned hospitalizations with high associated costs. Numerous medications and specific guidelines are available to prevent nausea and vomiting in patients with cancer. Specifically, the combination of two classes of medications (serotonin inhibitors + neurokinin type 1 inhibitors) has been shown to provide the greatest benefit. However, hospital

For patients with fibrodysplasia ossificans progressiva (FOP), prompt diagnosis and effective management are crucial to preventing disease exacerbation and improving quality of life. In this convenient three-part micro-learning video library, expert faculty will review the pathophysiology of FOP, latest diagnostic strategies, clinical evidence related to emerging therapeutics that are poised to revolutionize the FOP treatment paradigm, and strategies for personalized, patient-centered FOP care.

Background/Purpose: Patients with untreated immune-mediated inflammatory diseases, such as RA, PsA, and AS, are at increased risk for major adverse cardiovascular events (MACE) and venous thromboembolic events (VTE) compared with the general population.

The purpose of this analysis was to describe the events and risk factors for MACE and VTE in the RA, PsA, and AS clinical trial programs of the Janus kinase (JAK) inhibitor, upadacitinib (UPA).

Methods: Treatment-emergent adverse events (TEAEs)

Research is ongoing to explore all potential uses for circulating tumor DNA to help reduce the global burden of colorectal cancer.

Circulating tumor (ctDNA) technology has the potential to improve diagnosis, treatment, and monitoring of patients with colorectal cancer (CRC).1 Research is ongoing to explore all potential uses for ctDNA to help reduce the global burden of CRC.1-4 Although CRC is preventable and curable when diagnosed early, most patients receive diagnoses at advanced stages.2 Ear